Pub Date : 2025-12-13DOI: 10.1016/j.jhep.2025.12.006
Milan J. Sonneveld, Harry L.A. Janssen
There are many new compounds in development for the treatment of chronic hepatitis B. Although major on-treatment HBsAg declines can be achieved with some of these drugs, achievement of post-treatment sustained HBsAg loss with undetectable HBV DNA (functional cure) remains challenging; especially in patients with high pretreatment HBsAg levels. Interestingly, a substantial proportion of patients in these trials that did not experience HBsAg loss, did maintain low HBsAg levels after withdrawal of study treatments. Based on data from natural history studies and studies on finite treatment with currently available agents, off-treatment sustained low HBsAg levels with low or undetectable HBV DNA levels (referred to as partial cure) is associated with excellent virological and clinical outcomes. In this expert opinion article, we argue that it is important to shift focus from HBsAg loss as the sole endpoint of HBV trials to a more individualized assessment of response that also considers partial cure (defined as off-treatment sustained low HBsAg with undetectable HBV DNA, potentially combined with other biomarkers) as a favorable treatment outcome. Such a strategy could help increase the number of patients considered responders to treatment, and as such could potentially extend eligibility for novel treatments to more CHB patients who can experience significant benefits.
{"title":"Individualizing endpoints in chronic HBV treatment: HBsAg loss and beyond","authors":"Milan J. Sonneveld, Harry L.A. Janssen","doi":"10.1016/j.jhep.2025.12.006","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.12.006","url":null,"abstract":"There are many new compounds in development for the treatment of chronic hepatitis B. Although major on-treatment HBsAg declines can be achieved with some of these drugs, achievement of post-treatment sustained HBsAg loss with undetectable HBV DNA (functional cure) remains challenging; especially in patients with high pretreatment HBsAg levels. Interestingly, a substantial proportion of patients in these trials that did not experience HBsAg loss, did maintain low HBsAg levels after withdrawal of study treatments. Based on data from natural history studies and studies on finite treatment with currently available agents, off-treatment sustained low HBsAg levels with low or undetectable HBV DNA levels (referred to as partial cure) is associated with excellent virological and clinical outcomes. In this expert opinion article, we argue that it is important to shift focus from HBsAg loss as the sole endpoint of HBV trials to a more individualized assessment of response that also considers partial cure (defined as off-treatment sustained low HBsAg with undetectable HBV DNA, potentially combined with other biomarkers) as a favorable treatment outcome. Such a strategy could help increase the number of patients considered responders to treatment, and as such could potentially extend eligibility for novel treatments to more CHB patients who can experience significant benefits.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"152 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145760355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1016/j.jhep.2025.11.029
Athanasios Mamarelis, Matthew Byott, Stuart Flanagan, Indrajit Gosh, Eleni Nastouli
Section snippets
Authors' contributions
Writing the Manuscript: Athanasios Mamarelis, Matthew Byott, Stuart Flanagan, Eleni NastouliNext-Generation Sequencing (NGS): Jude HeaneyBioinformatic Analysis: Matthew Byott
Data availability statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Financial support
The authors received no financial support for the research, authorship, and/or publication of this article.
Conflict of interest
The authors declare no conflicts of interest.Please refer to the accompanying ICMJE disclosure forms for further details.
Acknowledgement
We thank Dr Jude Heaney and Dr Paul Grant (HSL Laboratories) for their valuable assistance with the HBV NGS testing.
部分片段作者贡献撰写稿件：Athanasios Mamarelis， Matthew Byott, Stuart Flanagan， Eleni nastoul下一代测序（NGS）： Jude heaney生物信息学分析：Matthew byott数据可用性声明支持本研究结果的数据可根据合理要求从通讯作者处获得。作者在研究、撰写和/或发表本文时未获得任何经济支持。利益冲突作者声明无利益冲突。详情请参阅随附的ICMJE披露表格。我们感谢Jude Heaney博士和Paul Grant博士（HSL实验室）对HBV NGS检测的宝贵帮助。
{"title":"Addressing the Risk of HBV Transmission in Serodifferent Partners","authors":"Athanasios Mamarelis, Matthew Byott, Stuart Flanagan, Indrajit Gosh, Eleni Nastouli","doi":"10.1016/j.jhep.2025.11.029","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.11.029","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>Writing the Manuscript: Athanasios Mamarelis, Matthew Byott, Stuart Flanagan, Eleni NastouliNext-Generation Sequencing (NGS): Jude HeaneyBioinformatic Analysis: Matthew Byott</section></section><section><section><h2>Data availability statement</h2>The data that support the findings of this study are available from the corresponding author upon reasonable request.</section></section><section><section><h2>Financial support</h2>The authors received no financial support for the research, authorship, and/or publication of this article.</section></section><section><section><h2>Conflict of interest</h2>The authors declare no conflicts of interest.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section><section><section><h2>Acknowledgement</h2>We thank Dr Jude Heaney and Dr Paul Grant (HSL Laboratories) for their valuable assistance with the HBV NGS testing.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"6 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145717623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1016/j.jhep.2025.11.014
David C. Trampert
{"title":"Viral infection as a trigger for primary sclerosing cholangitis in genetically susceptible individuals","authors":"David C. Trampert","doi":"10.1016/j.jhep.2025.11.014","DOIUrl":"10.1016/j.jhep.2025.11.014","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"84 2","pages":"Pages 477-478"},"PeriodicalIF":33.0,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145732193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1016/j.jhep.2025.12.004
Huigang Li, Ruijie Zhao, Shusen Zheng, Xiao Xu, Di Lu
Section snippets
Ethical approval
Ethical approval for the HBV-related HCC cohort was obtained from the Ethics Committee of two centers (Shulan (Hangzhou) Hospital and the First Affiliated Hospital, Zhejiang University School of Medicine), consistent with prior research (approval IDs: No. 2020-510 and No. KY2021014).
Authors' contributions
Li H and Zhao R performed the analyses. Li H and Lu D drafted the manuscript. Xu X and Zheng S revised the manuscript.
Data availability statement
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
Financial support
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
{"title":"Recurrence pattern for HBV-related HCC after liver transplantation in the antiviral era","authors":"Huigang Li, Ruijie Zhao, Shusen Zheng, Xiao Xu, Di Lu","doi":"10.1016/j.jhep.2025.12.004","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.12.004","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Ethical approval</h2>Ethical approval for the HBV-related HCC cohort was obtained from the Ethics Committee of two centers (Shulan (Hangzhou) Hospital and the First Affiliated Hospital, Zhejiang University School of Medicine), consistent with prior research (approval IDs: No. 2020-510 and No. KY2021014).</section></section><section><section><h2>Authors' contributions</h2>Li H and Zhao R performed the analyses. Li H and Lu D drafted the manuscript. Xu X and Zheng S revised the manuscript.</section></section><section><section><h2>Data availability statement</h2>The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.</section></section><section><section><h2>Financial support</h2>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</section></section><section><section><h2>Declaration of Competing Interest</h2>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"19 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145728928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1016/j.jhep.2025.12.003
Jing Liu, Jinyi Wu, Bin Wang
{"title":"Associations of accelerated biological aging with steatotic liver disease and fibrosis","authors":"Jing Liu, Jinyi Wu, Bin Wang","doi":"10.1016/j.jhep.2025.12.003","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.12.003","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"10 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145732194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-08DOI: 10.1016/j.jhep.2025.12.001
Chia-Lang Hsu, Yung-Yeh Su, Da-Liang Ou, Chiun Hsu
Section snippets
Authors' contributions
Chiun Hsu served as a principal investigator and designed the study. Yung-Yeh Su performed statistical analyses for the clinical part of the study. Chia-Lang Hsu and Da-Liang Ou performed statistical analyses for the biomarker study. Chiun Hsu and Yung-Yeh Su wrote and/or edited the manuscript. All authors provided comments on and approved the final manuscript.
Financial support
This study was supported by grant 07D4-1CABMS2217 from National Health Research Institutes, Taiwan, and MOHW114-TDU-B-221-144007 from Ministry of Health and Welfare, Taiwan.
Conflict of interest
CH received research fundings (to the institution) from Bristol-Myers Squibb/ ONO, GoldenBiotech, IPSEN, Roche and honorarium from AstraZeneca, Bristol-Myers Squibb/ONO, Eisai, MSD, and Roche. Other authors have no relevant conflict of interests to declare.Please refer to the accompanying ICMJE disclosure forms for further details.
{"title":"Reply to: “Comment on nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration”","authors":"Chia-Lang Hsu, Yung-Yeh Su, Da-Liang Ou, Chiun Hsu","doi":"10.1016/j.jhep.2025.12.001","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.12.001","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>Chiun Hsu served as a principal investigator and designed the study. Yung-Yeh Su performed statistical analyses for the clinical part of the study. Chia-Lang Hsu and Da-Liang Ou performed statistical analyses for the biomarker study. Chiun Hsu and Yung-Yeh Su wrote and/or edited the manuscript. All authors provided comments on and approved the final manuscript.</section></section><section><section><h2>Financial support</h2>This study was supported by grant 07D4-1CABMS2217 from National Health Research Institutes, Taiwan, and MOHW114-TDU-B-221-144007 from Ministry of Health and Welfare, Taiwan.</section></section><section><section><h2>Conflict of interest</h2>CH received research fundings (to the institution) from Bristol-Myers Squibb/ ONO, GoldenBiotech, IPSEN, Roche and honorarium from AstraZeneca, Bristol-Myers Squibb/ONO, Eisai, MSD, and Roche. Other authors have no relevant conflict of interests to declare.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"20 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145704236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-08DOI: 10.1016/j.jhep.2025.11.027
Verena Keitel, Michael C. Kreissl, Tobias Goetze, Carola Dröge, Christina Katharina Kuhn, Nhu-Nguyen Pham, Dennis Löffler, Dominique Borie, Jens Schreiber, Martin Boettcher, Katrin Hippe, Maciej Pech, Martin Mikusko, Ulrike Köhl, Denise Walther, Kristin Reiche, Dimitrios Mougiakakos
IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder in which IgG4+ B cells and T cells interact to drive chronic organ inflammation. Patients with multiorgan involvement may become refractory to standard therapy, resulting in progressive organ damage and risk of organ failure. Here, we report a patient with treatment-refractory multiorgan IgG4-RD treated with CD19-directed CAR T cells and describe the clinical and immunologic effects over more than 12 months of follow-up. A 60-year-old man with IgG4-RD involving the pancreas, hepatobiliary tract, and lungs refractory to long-term immunosuppression received autologous CD19-directed CAR T cells. Disease course was monitored longitudinally, and peripheral blood underwent multimodal immune profiling. CAR T cell therapy was well tolerated, with only grade 1 cytokine release syndrome, no neurotoxicity, and transient cytopenias without infections. Treatment induced B cell aplasia lasting six months, and serum IgG4 normalized by month 8 and remained within the reference range. FAPI PET/CT demonstrated regression of fibroinflammatory activity, accompanied by improved lung function and quality of life. Immunosuppressive therapy was completely discontinued without disease flares for more than 12 months. B cell reconstitution consisted predominantly of naïve and transitional subsets. This was paralleled by a decline in T follicular helper cells and CD4+ cytotoxic T cells and attenuation of fibro-inflammatory and B cell–mediated signaling networks on interactome analyses. In this treatment-refractory case of multiorgan IgG4-RD, CD19-directed CAR T cell therapy induced durable, treatment-free remission with normalization of serum IgG4 and improvement across multiple clinical endpoints. Multimodal immune profiling indicates that CAR T cells can reset the B cell compartment and dampen pathogenic T cell and stromal interactions, supporting prospective evaluation of CAR T cell therapy in IgG4-RD.
{"title":"CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement","authors":"Verena Keitel, Michael C. Kreissl, Tobias Goetze, Carola Dröge, Christina Katharina Kuhn, Nhu-Nguyen Pham, Dennis Löffler, Dominique Borie, Jens Schreiber, Martin Boettcher, Katrin Hippe, Maciej Pech, Martin Mikusko, Ulrike Köhl, Denise Walther, Kristin Reiche, Dimitrios Mougiakakos","doi":"10.1016/j.jhep.2025.11.027","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.11.027","url":null,"abstract":"IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder in which IgG4<sup>+</sup> B cells and T cells interact to drive chronic organ inflammation. Patients with multiorgan involvement may become refractory to standard therapy, resulting in progressive organ damage and risk of organ failure. Here, we report a patient with treatment-refractory multiorgan IgG4-RD treated with CD19-directed CAR T cells and describe the clinical and immunologic effects over more than 12 months of follow-up. A 60-year-old man with IgG4-RD involving the pancreas, hepatobiliary tract, and lungs refractory to long-term immunosuppression received autologous CD19-directed CAR T cells. Disease course was monitored longitudinally, and peripheral blood underwent multimodal immune profiling. CAR T cell therapy was well tolerated, with only grade 1 cytokine release syndrome, no neurotoxicity, and transient cytopenias without infections. Treatment induced B cell aplasia lasting six months, and serum IgG4 normalized by month 8 and remained within the reference range. FAPI PET/CT demonstrated regression of fibroinflammatory activity, accompanied by improved lung function and quality of life. Immunosuppressive therapy was completely discontinued without disease flares for more than 12 months. B cell reconstitution consisted predominantly of naïve and transitional subsets. This was paralleled by a decline in T follicular helper cells and CD4<sup>+</sup> cytotoxic T cells and attenuation of fibro-inflammatory and B cell–mediated signaling networks on interactome analyses. In this treatment-refractory case of multiorgan IgG4-RD, CD19-directed CAR T cell therapy induced durable, treatment-free remission with normalization of serum IgG4 and improvement across multiple clinical endpoints. Multimodal immune profiling indicates that CAR T cells can reset the B cell compartment and dampen pathogenic T cell and stromal interactions, supporting prospective evaluation of CAR T cell therapy in IgG4-RD.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"135 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145704233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Data availability statement (delete if not applicable)
The transcriptome (RNA-seq) data generated in this study have been deposited in the Genome Sequence Archive of the National Genomics Data Center at the China National Center for Bioinformation/Beijing Institute of Genomics of the Chinese Academy of Sciences (GSA: CRA018701), which is publicly accessible (https://ngdc.cncb.ac.cn/gsa). The mass spectrometry proteomics data have been deposited in the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier, PXD055467
Authors' contributions
Beicheng Sun and Dengqiu Xu conceptualized the project. Dengqiu Xu, Zehua Zhang, Ting Fang, and Pengkai Wu performed the experiments, generated and analyzed the data. Dengqiu Xu and Zehua Zhang wrote the manuscript. Beicheng Sun and Dengqiu Xu provided conceptual inputs and suggestions into the manuscript.
Financial support
This work was supported by grants from the Anhui Provincial Natural Science Foundation (Grant No. 2408085Y041), the Key Project of Natural Science Research of Anhui Provincial Department of Education (Grant No. 2024AH050824) and the Anhui Provincial Natural Science Foundation and the State Key Program of the National Natural Science Foundation of China (Grant Nos. 82120108012, 81930086).
Conflict of interest
The authors have declared that no competing interest exists.Please refer to the accompanying ICMJE disclosure forms for further details.
{"title":"Hepatocyte-specific ablation of LONP1 disrupts liver glucose homeostasis in mice","authors":"Zehua Zhang, Ting Fang, Pengkai Wu, Beicheng Sun, Dengqiu Xu","doi":"10.1016/j.jhep.2025.11.028","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.11.028","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Data availability statement (delete if not applicable)</h2>The transcriptome (RNA-seq) data generated in this study have been deposited in the Genome Sequence Archive of the National Genomics Data Center at the China National Center for Bioinformation/Beijing Institute of Genomics of the Chinese Academy of Sciences (GSA: CRA018701), which is publicly accessible (<span><span>https://ngdc.cncb.ac.cn/gsa</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>). The mass spectrometry proteomics data have been deposited in the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier, PXD055467</section></section><section><section><h2>Authors' contributions</h2>Beicheng Sun and Dengqiu Xu conceptualized the project. Dengqiu Xu, Zehua Zhang, Ting Fang, and Pengkai Wu performed the experiments, generated and analyzed the data. Dengqiu Xu and Zehua Zhang wrote the manuscript. Beicheng Sun and Dengqiu Xu provided conceptual inputs and suggestions into the manuscript.</section></section><section><section><h2>Financial support</h2>This work was supported by grants from the Anhui Provincial Natural Science Foundation (Grant No. 2408085Y041), the Key Project of Natural Science Research of Anhui Provincial Department of Education (Grant No. 2024AH050824) and the Anhui Provincial Natural Science Foundation and the State Key Program of the National Natural Science Foundation of China (Grant Nos. 82120108012, 81930086).</section></section><section><section><h2>Conflict of interest</h2>The authors have declared that no competing interest exists.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"93 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145704238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-04DOI: 10.1016/j.jhep.2025.11.011
Cornelius Engelmann
{"title":"Decoding the metabolic dialogue between hepatocytes and macrophages driving liver regeneration","authors":"Cornelius Engelmann","doi":"10.1016/j.jhep.2025.11.011","DOIUrl":"10.1016/j.jhep.2025.11.011","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"84 2","pages":"Pages 475-476"},"PeriodicalIF":33.0,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145673827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：